Most Read Articles
2 years ago
Catecholamines may regulate serum HDL cholesterol level, abdominal visceral and subcutaneous fat mass in men with pheochromocytoma, based on a cross-sectional and longitudinal follow-up study.
6 days ago
There is a growing number of targeted therapies being approved for use in cancer therapy in the home setting, and this poses a potential risk among family member and caregivers, particularly those of reproductive risk age, a recent study suggests.
2 years ago

Advanced endoscopic devices can significantly improve the detection rates of colorectal polyps and tumors beyond standard colonoscopy, which has a miss rate of about 25 percent, reported speakers at the “Inventor’s Corner” session of the conference.

Christina Lau, 3 years ago

In patients with metastatic breast cancer who failed to clear circulating tumor cells (CTCs) after one cycle of first-line chemotherapy, switching to a different chemotherapy does not improve survival or delay progression, the phase III SWOG S0500 trial has shown.    

Family members, caregivers must take precautions from exposure to targeted drugs

6 days ago
ETC-206 is a form of target therapy which specifically targets and inhibits Mnk enzyme in cancer cells.

There is a growing number of targeted therapies being approved for use in cancer therapy in the home setting, and this poses a potential risk among family member and caregivers, particularly those of reproductive risk age, a recent study suggests.

The findings show that most of the oral targeted therapeutics have not been tested for carcinogenicity and that the genotoxicity data are mixed. However, majority of these drugs show adverse reproductive effects, of which some are severe.

Furthermore, data that are currently available do not permit the possibility of a health hazard from inappropriate handling of drugs and contaminated patients’ waste to be ignored, especially in a long-term home setting.

There is a need for overall basic education and related precautions in order to protect family members and caregivers from indirect or direct exposure to these drugs, according to researchers, adding that further research and discussion on this subject are warranted.

In this study, researchers performed a systematic literature review and summarized the known adverse health effect of 32 oral targeted therapeutics. They particularly assessed the carcinogenicity, genotoxicity and embryo-foetal toxicity, together with the route of excretion.

“With the growing number of oral targeted therapies being approved for use in cancer therapy, the potential for long-term administration of these drugs to cancer patients is expanding,” researchers said.

“The use of these drugs in the home setting has the potential to expose family members and caregivers to them either through direct contact with the drugs or indirectly by exposure to the parent compounds and/or their active metabolites in contaminated patients’ waste,” they added.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Oncology - Malaysia digital copy today!
DOWNLOAD
Editor's Recommendations
Most Read Articles
2 years ago
Catecholamines may regulate serum HDL cholesterol level, abdominal visceral and subcutaneous fat mass in men with pheochromocytoma, based on a cross-sectional and longitudinal follow-up study.
6 days ago
There is a growing number of targeted therapies being approved for use in cancer therapy in the home setting, and this poses a potential risk among family member and caregivers, particularly those of reproductive risk age, a recent study suggests.
2 years ago

Advanced endoscopic devices can significantly improve the detection rates of colorectal polyps and tumors beyond standard colonoscopy, which has a miss rate of about 25 percent, reported speakers at the “Inventor’s Corner” session of the conference.

Christina Lau, 3 years ago

In patients with metastatic breast cancer who failed to clear circulating tumor cells (CTCs) after one cycle of first-line chemotherapy, switching to a different chemotherapy does not improve survival or delay progression, the phase III SWOG S0500 trial has shown.